Literature DB >> 24459991

Sox9 reprogrammed dermal fibroblasts undergo hypertrophic differentiation in vitro and trigger endochondral ossification in vivo.

Wai Long Tam1, Dorien F O, Kunihiko Hiramatsu, Noriyuki Tsumaki, Frank P Luyten, Scott J Roberts.   

Abstract

Strategies for bone regeneration are undergoing a paradigm shift, moving away from the replication of end-stage bone tissue and instead aiming to recapture the initial events of fracture repair. Although this is known to resemble endochondral bone formation, chondrogenic cell types with favorable proliferative and hypertrophic differentiation properties are lacking. Recent advances in cellular reprogramming have allowed the creation of alternative cell populations with specific properties through the forced expression of transcription factors. Herein, we investigated the in vitro hypertrophic differentiation and in vivo tissue formation capacity of induced chondrogenic cells (iChon cells) obtained through direct reprogramming. In vitro hypertrophic differentiation was detected in iChon cells that contained a doxycycline-inducible expression system for Klf4, cMyc, and Sox9. Furthermore, endochondral bone formation was detected after implantation in nude mice. The bone tissue was derived entirely from host origin, whereas cartilage tissue contained cells from both host and donor. The results obtained highlight the promise of cellular reprogramming for the creation of functional skeletal cells that can be used for novel bone healing strategies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24459991      PMCID: PMC3920914          DOI: 10.1089/cell.2013.0060

Source DB:  PubMed          Journal:  Cell Reprogram        ISSN: 2152-4971            Impact factor:   1.987


  35 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  The fate of the terminally differentiated chondrocyte: evidence for microenvironmental regulation of chondrocyte apoptosis.

Authors:  Christopher S Adams; Irving M Shapiro
Journal:  Crit Rev Oral Biol Med       Date:  2002

3.  Trans-differentiation of hypertrophic chondrocytes into cells capable of producing a mineralized bone matrix.

Authors:  H I Roach
Journal:  Bone Miner       Date:  1992-10

4.  Dominance of SOX9 function over RUNX2 during skeletogenesis.

Authors:  Guang Zhou; Qiping Zheng; Feyza Engin; Elda Munivez; Yuqing Chen; Eiman Sebald; Deborah Krakow; Brendan Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-01       Impact factor: 11.205

Review 5.  Circulating cells with osteogenic potential.

Authors:  Sundeep Khosla; Guiti Z Eghbali-Fatourechi
Journal:  Ann N Y Acad Sci       Date:  2006-04       Impact factor: 5.691

6.  Nkx3.2/Bapx1 acts as a negative regulator of chondrocyte maturation.

Authors:  Sylvain Provot; Hervé Kempf; L Charles Murtaugh; Ung-il Chung; Dae-Won Kim; Jay Chyung; Henry M Kronenberg; Andrew B Lassar
Journal:  Development       Date:  2006-01-18       Impact factor: 6.868

7.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

8.  VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation.

Authors:  H P Gerber; T H Vu; A M Ryan; J Kowalski; Z Werb; N Ferrara
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

9.  Dual effects of the membrane-anchored MMP regulator RECK on chondrogenic differentiation of ATDC5 cells.

Authors:  Shunya Kondo; Chisa Shukunami; Yoko Morioka; Naoya Matsumoto; Rei Takahashi; Junseo Oh; Tadao Atsumi; Akihiro Umezawa; Akira Kudo; Hitoshi Kitayama; Yuji Hiraki; Makoto Noda
Journal:  J Cell Sci       Date:  2007-02-13       Impact factor: 5.285

10.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.

Authors:  Kazutoshi Takahashi; Koji Tanabe; Mari Ohnuki; Megumi Narita; Tomoko Ichisaka; Kiichiro Tomoda; Shinya Yamanaka
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

View more
  7 in total

Review 1.  From skeletal development to the creation of pluripotent stem cell-derived bone-forming progenitors.

Authors:  Wai Long Tam; Frank P Luyten; Scott J Roberts
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

Review 2.  Endochondral ossification for enhancing bone regeneration: converging native extracellular matrix biomaterials and developmental engineering in vivo.

Authors:  S Connor Dennis; Cory J Berkland; Lynda F Bonewald; Michael S Detamore
Journal:  Tissue Eng Part B Rev       Date:  2014-12-04       Impact factor: 6.389

3.  Generation of a Bone Organ by Human Adipose-Derived Stromal Cells Through Endochondral Ossification.

Authors:  Rik Osinga; Nunzia Di Maggio; Atanas Todorov; Nima Allafi; Andrea Barbero; Frédéric Laurent; Dirk Johannes Schaefer; Ivan Martin; Arnaud Scherberich
Journal:  Stem Cells Transl Med       Date:  2016-06-22       Impact factor: 6.940

Review 4.  Bone physiology as inspiration for tissue regenerative therapies.

Authors:  Diana Lopes; Cláudia Martins-Cruz; Mariana B Oliveira; João F Mano
Journal:  Biomaterials       Date:  2018-09-17       Impact factor: 12.479

5.  Biomimetic strategies for fracture repair: Engineering the cell microenvironment for directed tissue formation.

Authors:  Wollis J Vas; Mittal Shah; Rawiya Al Hosni; Helen C Owen; Scott J Roberts
Journal:  J Tissue Eng       Date:  2017-04-24       Impact factor: 7.813

Review 6.  Cellular reprogramming for clinical cartilage repair.

Authors:  Britta J H Driessen; Colin Logie; Lucienne A Vonk
Journal:  Cell Biol Toxicol       Date:  2017-01-31       Impact factor: 6.691

7.  Dracohodin Perochlorate Stimulates Fibroblast Proliferation via EGFR Activation and Downstream ERK/CREB and PI3K/Akt/mTOR Pathways In Vitro.

Authors:  Lin Liu; Xiaowen Jiang; Wenhui Yu
Journal:  Evid Based Complement Alternat Med       Date:  2019-08-25       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.